Expertise in
1
conditions

Yvette Drew

Framlington Place, 
Newcastle Upon Tyne, ENG, GB 
Expertise in
1
conditions
Framlington Place, 
Newcastle Upon Tyne, ENG, GB 

Overview

Yvette Drew practices practicing medicine in Newcastle Upon Tyne, United Kingdom.

Ms. Drew is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Ovarian Cancer, Cervical Cancer, Ataxia-Telangiectasia, and Vulvar Cancer.

She is actively involved in clinical research, co-authoring 49 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Framlington Place, Newcastle Upon Tyne, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: August 01, 2023
Intervention Type: Biological
Study Drug: Enapotamab vedotin 
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

49 Total Publications

Interpreting homologous recombination deficiency in rare gynecological cancers: A case of primary mucinous endometrial adenocarcinoma of gastrointestinal type.
Interpreting homologous recombination deficiency in rare gynecological cancers: A case of primary mucinous endometrial adenocarcinoma of gastrointestinal type.
Journal: Gynecologic oncology reports
Published: June 23, 2026

Frequently Asked Questions about Yvette Drew

Is Yvette Drew a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Yvette Drew is classified as an Distinguished expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yvette Drew participate in research or clinical trials?

Yes. Yvette Drew has published 49 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Yvette Drew's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Drew's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile